
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding is benefiting from a first FDA approval that validates its core science and materially de-risks the platform, with SAPPHIRE showing a clinically meaningful 2.2-point HFMSE improvement and ~98% of treated patients continuing into ONYX. The approved label is broad across SMA subtypes and ambulatory status, covering nearly 6,600 U.S. patients on SMN2-targeting therapy, while management’s expected roughly $310K of annual net revenue per typical patient and $11,659 WAC per 150-mg vial support a sizable launch opportunity. Concerns around fracture and reproductive language appear unlikely to meaningfully curtail uptake, especially given high physician enthusiasm, no contraindication, and the company’s expansion potential through subcutaneous apitegromab, SRK-439, and other neuromuscular programs.
Bears say
Scholar Rock Holding is viewed negatively because its lead opportunity faces payer duration risk, with insurers potentially treating Isembyld differently from SMN modifiers since it does not preserve motor neurons. The SAPPHIRE motor-scale gains were described as being on the smaller end of significance, and a roughly 2-point improvement may not justify monthly IV infusions for many patients, especially older and more stable ones. Additional downside comes from the possibility of unexpected real-world safety issues, an adverse EC regulatory decision for European sales, and pricing reform that could pressure reimbursement for rare disease products.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Scholar Rock Holding Corp (SRRK) Forecast
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares